People · Operator
Named in public records as an officer, director or promoter · active 2013–2024 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| ONL Therapeutics, Inc. | — | Biotechnology | Series C | $111.5M | $496.0M | 2024 |
| Navitor Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $68.2M | $686.4M | 2013 |
| Redona Therapeutics, Inc. | — | Biotechnology | Series C | $66.8M | $76.2M | 2018 |
| CoStim Pharmaceuticals Inc. | — | Pharmaceuticals | Series A | $10.0M | $309.9M | 2013 |
Marian Nakada at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Marian Nakada on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jean-Francois Formela | 2 | 17 |
| Luke Evnin | 2 | 12 |
| Michal Silverberg | 2 | 7 |
| Kazumi Shiosaki | 2 | 4 |
| Kevin Bitterman | 1 | 15 |
| Brian Gallagher | 1 | 11 |
| Alan Crane | 1 | 9 |
| Briggs Morrison | 1 | 8 |
| Rajeev Dadoo | 1 | 7 |
| Josh Resnick | 1 | 7 |
| Roger Kitterman | 1 | 5 |
| Paul Friedman | 1 | 5 |
| Aaron Fletcher | 1 | 5 |
| John Creecy | 1 | 5 |
| THOMAS HUGHES | 1 | 4 |
| Stella Robertson | 1 | 4 |
| Vinzenz Ploerer | 1 | 4 |
| David Madden | 1 | 3 |
| Robert Millman | 1 | 3 |
| Rafael Castilla | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.